

# Juan C Hernandez-Boluda

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4449367/juan-c-hernandez-boluda-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

150  
papers

3,416  
citations

33  
h-index

53  
g-index

162  
ext. papers

4,031  
ext. citations

5.3  
avg, IF

4.77  
L-index

| #   | Paper   | IF   | Citations |
|-----|---|------|-----------|
| 150 | BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. <i>Cancer Cell</i> , <b>2014</b> , 26, 428-442  | 24.3 | 233       |
| 149 | Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. <i>Leukemia</i> , <b>1999</b> , 13, 150-4   | 10.7 | 179       |
| 148 | Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. <i>Blood</i> , <b>2010</b> , 116, 1205-10; quiz 1387   | 2.2  | 175       |
| 147 | Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. <i>Blood</i> , <b>2012</b> , 119, 1363-9   | 2.2  | 156       |
| 146 | Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. <i>Leukemia</i> , <b>2007</b> , 21, 143-50 | 10.7 | 150       |
| 145 | Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. <i>British Journal of Haematology</i> , <b>2004</b> , 127, 399-403   | 4.5  | 111       |
| 144 | Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. <i>Leukemia</i> , <b>2007</b> , 21, 1218-23  | 10.7 | 97        |
| 143 | Quantification of DNA in plasma by an automated real-time PCR assay (cytomegalovirus PCR kit) for surveillance of active cytomegalovirus infection and guidance of preemptive therapy for allogeneic hematopoietic stem cell transplant recipients. <i>Journal of Clinical Microbiology</i> , <b>2008</b> , 46, 3311-8        | 9.7  | 96        |
| 142 | Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. <i>Haematologica</i> , <b>2016</b> , 101, 926-31  | 6.6  | 91        |
| 141 | Allogeneic transplantation of CD34(+) selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34(+) cells?. <i>Blood</i> , <b>2001</b> , 98, 2352-7  | 2.2  | 66        |
| 140 | Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia. <i>British Journal of Haematology</i> , <b>2006</b> , 134, 184-6  | 4.5  | 63        |
| 139 | Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients. <i>Blood Cancer Journal</i> , <b>2016</b> , 6, e493   | 7    | 55        |
| 138 | Clinical evaluation of the European LeukaemiaNet criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. <i>British Journal of Haematology</i> , <b>2011</b> , 152, 81-8  | 4.5  | 55        |
| 137 | High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. <i>Leukemia</i> , <b>2016</b> , 30, 2032-2038   | 10.7 | 55        |
| 136 | Reconstitution of CMV pp65 and IE-1-specific IFN- $\gamma$ CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT. <i>Bone Marrow Transplantation</i> , <b>2011</b> , 46, 1437-43  | 4.4  | 54        |
| 135 | Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFN $\gamma$ CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients. <i>Bone Marrow Transplantation</i> , <b>2010</b> , 45, 543-9   | 4.4  | 49        |
| 134 | Danazol treatment of idiopathic myelofibrosis with severe anemia. <i>Haematologica</i> , <b>2000</b> , 85, 595-9  | 6.6  | 47        |

|     |   |      |    |
|-----|---|------|----|
| 133 | Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 603   | 5.3  | 46 |
| 132 | Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. <i>Annals of Hematology</i> , <b>2014</b> , 93, 2037-43   | 3    | 46 |
| 131 | High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. <i>Leukemia</i> , <b>2021</b> , 35, 485-493  | 10.7 | 45 |
| 130 | Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia. <i>Leukemia Research</i> , <b>2011</b> , 35, 1014-9   | 2.7  | 44 |
| 129 | JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis. <i>Haematologica</i> , <b>2007</b> , 92, 1717-8   | 6.6  | 44 |
| 128 | Impact of different strategies of second-line stem cell harvest on the outcome of autologous transplantation in poor peripheral blood stem cell mobilizers. <i>Bone Marrow Transplantation</i> , <b>2005</b> , 36, 847-53   | 4.4  | 43 |
| 127 | The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis. <i>Haematologica</i> , <b>2014</b> , 99, e55-7   | 6.6  | 42 |
| 126 | Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera. <i>British Journal of Haematology</i> , <b>2016</b> , 172, 786-93   | 4.5  | 41 |
| 125 | Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a study of the Spanish PETHEMA group. <i>Haematologica</i> , <b>2010</b> , 95, 1317-24  | 6.6  | 41 |
| 124 | Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. <i>Annals of Hematology</i> , <b>2015</b> , 94, 911-8   | 3    | 40 |
| 123 | Enumeration of cytomegalovirus-specific interferongamma CD8+ and CD4+ T cells early after allogeneic stem cell transplantation may identify patients at risk of active cytomegalovirus infection. <i>Haematologica</i> , <b>2008</b> , 93, 1434-6   | 6.6  | 39 |
| 122 | Danazol therapy for the anemia of myelofibrosis: assessment of efficacy with current criteria of response and long-term results. <i>Annals of Hematology</i> , <b>2015</b> , 94, 1791-6   | 3    | 37 |
| 121 | Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 2167-2171 | 4.7  | 35 |
| 120 | A polymorphism in the XPD gene predisposes to leukemic transformation and new nonmyeloid malignancies in essential thrombocythemia and polycythemia vera. <i>Blood</i> , <b>2012</b> , 119, 5221-8  | 2.2  | 35 |
| 119 | Genomic p16 abnormalities in the progression of chronic myeloid leukemia into blast crisis: a sequential study in 42 patients. <i>Experimental Hematology</i> , <b>2003</b> , 31, 204-10  | 3.1  | 35 |
| 118 | Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea. <i>Haematologica</i> , <b>2017</b> , 102, 103-109   | 6.6  | 33 |
| 117 | An assessment of the effect of human herpesvirus-6 replication on active cytomegalovirus infection after allogeneic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2010</b> , 16, 653-61  | 4.7  | 30 |
| 116 | JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. <i>American Journal of Hematology</i> , <b>2014</b> , 89, 517-23  | 7.1  | 29 |

|     |   |      |    |
|-----|---|------|----|
| 115 | Kinetics of cytomegalovirus (CMV) pp65 and IE-1-specific IFN $\gamma$ CD8+ and CD4+ T cells during episodes of viral DNAemia in allogeneic stem cell transplant recipients: potential implications for the management of active CMV infection. <i>Journal of Medical Virology</i> , <b>2010</b> , 82, 1208-15 | 19.7 | 28 |
| 114 | Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis. <i>Neurological Sciences</i> , <b>2017</b> , 38, 1213-1221  | 3.5  | 26 |
| 113 | Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients. <i>Leukemia and Lymphoma</i> , <b>2005</b> , 46, 717-22  | 1.9  | 25 |
| 112 | Assessment of peripheral blood lymphocyte subsets in idiopathic myelofibrosis. <i>European Journal of Haematology</i> , <b>2000</b> , 65, 104-8   | 3.8  | 25 |
| 111 | Imatinib mesylate (Gleevec, Glivec): a new therapy for chronic myeloid leukemia and other malignancies. <i>Drugs of Today</i> , <b>2002</b> , 38, 601-13  |      | 25 |
| 110 | Clinical Effectiveness of Influenza Vaccination After Allogeneic Hematopoietic Stem Cell Transplantation: A Cross-sectional, Prospective, Observational Study. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 68, 1894-1903  | 11.6 | 25 |
| 109 | Epidemiologic and Clinical Characteristics of Coronavirus and Bocavirus Respiratory Infections after Allogeneic Stem Cell Transplantation: A Prospective Single-Center Study. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 563-570  | 4.7  | 24 |
| 108 | Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 91  | 7    | 24 |
| 107 | Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study. <i>British Journal of Haematology</i> , <b>2013</b> , 161, 865-71  | 4.5  | 23 |
| 106 | XPC genetic polymorphisms correlate with the response to imatinib treatment in patients with chronic phase chronic myeloid leukemia. <i>American Journal of Hematology</i> , <b>2010</b> , 85, 482-6  | 7.1  | 23 |
| 105 | Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. <i>Haematologica</i> , <b>2003</b> , 88, 1117-22  | 6.6  | 22 |
| 104 | Clinical evaluation of the European LeukemiaNet response criteria in patients with essential thrombocythemia treated with anagrelide. <i>Annals of Hematology</i> , <b>2013</b> , 92, 771-5   | 3    | 21 |
| 103 | Blast crisis of Ph-positive chronic myeloid leukemia with isochromosome 17q: report of 12 cases and review of the literature. <i>Leukemia and Lymphoma</i> , <b>2000</b> , 38, 83-90  | 1.9  | 20 |
| 102 | Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 358-366                      | 4.7  | 20 |
| 101 | Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 764-771   | 4.5  | 19 |
| 100 | Myelofibrosis with myeloid metaplasia in adult individuals 30 years old or younger: presenting features, evolution and survival. <i>European Journal of Haematology</i> , <b>2001</b> , 66, 324-7   | 3.8  | 19 |
| 99  | Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , <b>2018</b> , 8, 25  | 7    | 18 |
| 98  | Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia. <i>British Journal of Haematology</i> , <b>2018</b> , 181, 397-400  | 4.5  | 18 |

|    |   |      |    |
|----|---|------|----|
| 97 | A Time-to-Event Model for Acute Kidney Injury after Reduced-Intensity Conditioning Stem Cell Transplantation Using a Tacrolimus- and Sirolimus-based Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , <b>2017</b> , 23, 1177-1185  | 4.7  | 17 |
| 96 | Sirolimus exposure and the occurrence of cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation. <i>American Journal of Transplantation</i> , <b>2018</b> , 18, 2885-2894   | 8.7  | 17 |
| 95 | Functional polymorphisms in SOCS1 and PTPN22 genes correlate with the response to imatinib treatment in newly diagnosed chronic-phase chronic myeloid leukemia. <i>Leukemia Research</i> , <b>2012</b> , 36, 174-81   | 2.7  | 17 |
| 94 | Community-acquired respiratory virus lower respiratory tract disease in allogeneic stem cell transplantation recipient: Risk factors and mortality from pulmonary virus-bacterial mixed infections. <i>Transplant Infectious Disease</i> , <b>2018</b> , 20, e12926   | 2.7  | 16 |
| 93 | Impact of cytomegalovirus DNAemia on overall and non-relapse mortality in allogeneic stem cell transplant recipients. <i>Transplant Infectious Disease</i> , <b>2017</b> , 19, e12717   | 2.7  | 15 |
| 92 | Determinants of survival in myelofibrosis patients undergoing allogeneic hematopoietic cell transplantation. <i>Leukemia</i> , <b>2021</b> , 35, 215-224  | 10.7 | 15 |
| 91 | Target hematologic values in the management of essential thrombocythemia and polycythemia vera. <i>European Journal of Haematology</i> , <b>2015</b> , 94, 4-11   | 3.8  | 14 |
| 90 | Prognostic factors in chronic myeloid leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , <b>2009</b> , 22, 343-53   | 4.2  | 14 |
| 89 | Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients. <i>Annals of Hematology</i> , <b>2019</b> , 98, 321-330   | 3    | 14 |
| 88 | Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 21  | 7    | 14 |
| 87 | Predictive factors for anemia response to erythropoiesis-stimulating agents in myelofibrosis. <i>European Journal of Haematology</i> , <b>2017</b> , 98, 407-414  | 3.8  | 13 |
| 86 | Cytomegalovirus (CMV) infection and risk of mortality in allogeneic hematopoietic stem cell transplantation (Allo-HSCT): A systematic review, meta-analysis, and meta-regression analysis. <i>American Journal of Transplantation</i> , <b>2019</b> , 19, 2479-2494   | 8.7  | 13 |
| 85 | A risk-adapted approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic stem cell transplantation recipients with oral ribavirin therapy: A pilot study. <i>Transplant Infectious Disease</i> , <b>2017</b> , 19, e12729  | 2.7  | 12 |
| 84 | Long-term results of prednisone treatment for the anemia of myelofibrosis. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 120-4   | 1.9  | 12 |
| 83 | Risk factors for non-melanoma skin cancer in patients with essential thrombocythemia and polycythemia vera. <i>European Journal of Haematology</i> , <b>2016</b> , 96, 285-90   | 3.8  | 12 |
| 82 | Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 16  | 7    | 12 |
| 81 | Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 2147-2159                              | 4.4  | 11 |
| 80 | Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of European society for blood and marrow transplantation (EBMT). <i>American Journal of Hematology</i> , <b>2021</b> , 96, 69-79 | 7.1  | 11 |

|    |  |      |    |
|----|--|------|----|
| 79 | Primary prophylaxis of invasive fungal infections with posaconazole or itraconazole in patients with acute myeloid leukaemia or high-risk myelodysplastic syndromes undergoing intensive cytotoxic chemotherapy: A real-world comparison. <i>Mycoses</i> , <b>2018</b> , 61, 206-212 | 5.2  | 11 |
| 78 | Cytomegalovirus DNAemia Burden and Mortality Following Allogeneic Hematopoietic Stem Cell Transplantation: An Area Under a Curve-Based Investigational Approach. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 67, 805-807   | 11.6 | 10 |
| 77 | Pulmonary cytomegalovirus (CMV) DNA shedding in allogeneic hematopoietic stem cell transplant recipients: Implications for the diagnosis of CMV pneumonia. <i>Journal of Infection</i> , <b>2019</b> , 78, 393-401   | 18.9 | 9  |
| 76 | miR-146a rs2431697 identifies myeloproliferative neoplasm patients with higher secondary myelofibrosis progression risk. <i>Leukemia</i> , <b>2020</b> , 34, 2648-2659   | 10.7 | 9  |
| 75 | Pre-engraftment cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: incidence, risk factors, and clinical outcomes. <i>Bone Marrow Transplantation</i> , <b>2019</b> , 54, 90-98  | 4.4  | 9  |
| 74 | Incidence, risk factors, and outcome of pulmonary invasive fungal disease after respiratory virus infection in allogeneic hematopoietic stem cell transplantation recipients. <i>Transplant Infectious Disease</i> , <b>2019</b> , 21, e13158  | 2.7  | 9  |
| 73 | Polymyositis after donor lymphocyte infusion. <i>International Journal of Hematology</i> , <b>2012</b> , 96, 386-9   | 2.3  | 9  |
| 72 | Idiopathic myelofibrosis associated with primary biliary cirrhosis. <i>Leukemia and Lymphoma</i> , <b>2002</b> , 43, 673-4   | 1.9  | 9  |
| 71 | Bone marrow transplantation for severe aplastic anemia: the Barcelona Hospital Clinic experience. <i>Haematologica</i> , <b>1999</b> , 84, 26-31   | 6.6  | 9  |
| 70 | Alleviating anemia and thrombocytopenia in myelofibrosis patients. <i>Expert Review of Hematology</i> , <b>2016</b> , 9, 489-96  | 2.8  | 8  |
| 69 | Surveillance for adenovirus DNAemia early after transplantation in adult recipients of unrelated-donor allogeneic stem cell transplants in the absence of clinically suspected infection. <i>Bone Marrow Transplantation</i> , <b>2011</b> , 46, 1484-6                              | 4.4  | 8  |
| 68 | Incidence, features, and outcomes of cytomegalovirus DNAemia in unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with post-transplantation cyclophosphamide. <i>Transplant Infectious Disease</i> , <b>2020</b> , 22, e13206                          | 2.7  | 8  |
| 67 | Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2019</b> , 25, 1022-1030                                   | 4.7  | 8  |
| 66 | Natural history of polycythemia vera and essential thrombocythemia presenting with splanchnic vein thrombosis. <i>Annals of Hematology</i> , <b>2020</b> , 99, 791-798   | 3    | 7  |
| 65 | Kinetics of torque teno virus DNA load in saliva and plasma following allogeneic hematopoietic stem cell transplantation. <i>Journal of Medical Virology</i> , <b>2018</b> , 90, 1438-1443   | 19.7 | 7  |
| 64 | Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine. <i>Annals of Hematology</i> , <b>2020</b> , 99, 527-537   | 3    | 7  |
| 63 | Reconstitution of cytomegalovirus-specific T-cell immunity following unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1347-1356                          | 4.4  | 6  |
| 62 | Successful treatment of hepatitis C virus infection with sofosbuvir and simeprevir in the early phase of an allogeneic stem cell transplant. <i>Transplant Infectious Disease</i> , <b>2016</b> , 18, 89-92  | 2.7  | 6  |



|    |   |      |   |
|----|---|------|---|
| 61 | Indirect and non-medical economic burden, quality-of-life, and disabilities of the myelofibrosis disease in Spain. <i>Journal of Medical Economics</i> , <b>2014</b> , 17, 435-41   | 2.4  | 6 |
| 60 | Single-agent therapy with oral mercaptopurine for nonlymphoid blast crisis of chronic myeloid leukemia. <i>Annals of Hematology</i> , <b>2001</b> , 80, 516-20  | 3    | 6 |
| 59 | Non-HodgkinB lymphoma following untreated essential thrombocythemia. <i>Leukemia and Lymphoma</i> , <b>2000</b> , 36, 421-3   | 1.9  | 6 |
| 58 | An investigation of the utility of plasma Cytomegalovirus (CMV) microRNA detection to predict CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients. <i>Medical Microbiology and Immunology</i> , <b>2020</b> , 209, 15-21  | 4    | 6 |
| 57 | Long-term follow-up of recovered MPN patients with COVID-19. <i>Blood Cancer Journal</i> , <b>2021</b> , 11, 115  | 7    | 6 |
| 56 | The effect of timing on community acquired respiratory virus infection mortality during the first year after allogeneic hematopoietic stem cell transplantation: a prospective epidemiological survey. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 431-440                   | 4.4  | 6 |
| 55 | Treatment of elderly patients with AML: results of an individualized approach. <i>Haematologica</i> , <b>1998</b> , 83, 34-9  | 6.6  | 6 |
| 54 | BCL2 gene polymorphisms and splicing variants in chronic myeloid leukemia. <i>Leukemia Research</i> , <b>2015</b> , 39, 1278-1278   | 2.7  | 5 |
| 53 | Prognostic risk models for transplant decision-making in myelofibrosis. <i>Annals of Hematology</i> , <b>2018</b> , 97, 813-820   | 3    | 5 |
| 52 | A polymorphism in the TYMP gene is associated with the outcome of HLA-identical sibling allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , <b>2013</b> , 88, 883-9   | 7.1  | 5 |
| 51 | An XRCC1 polymorphism is associated with the outcome of patients with lymphoma undergoing autologous stem cell transplant. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 1249-54   | 1.9  | 5 |
| 50 | Imatinib mesylate (STI571) treatment in patients with chronic-phase chronic myelogenous leukaemia previously submitted to autologous stem cell transplantation. <i>British Journal of Haematology</i> , <b>2003</b> , 120, 500-4  | 4.5  | 5 |
| 49 | Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 2237-2244 | 4.7  | 5 |
| 48 | European wide survey on allogeneic haematopoietic cell transplantation practice for myelofibrosis on behalf of the EBMT chronic malignancies working party. <i>Current Research in Translational Medicine</i> , <b>2021</b> , 69, 103267  | 3.7  | 5 |
| 47 | A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia. <i>PLoS ONE</i> , <b>2017</b> , 12, e0173532   | 3.7  | 4 |
| 46 | Current Treatment Options for Chronic Myeloid Leukemia Patients Failing Second-Generation Tyrosine Kinase Inhibitors. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,  | 5.1  | 4 |
| 45 | Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,  | 5.1  | 4 |
| 44 | Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. <i>Lancet Haematology</i> , <b>2021</b> , 8, e658-e665   | 14.6 | 4 |

|    |  |      |   |
|----|--|------|---|
| 43 | SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders.. <i>Journal of Hematology and Oncology</i> , <b>2022</b> , 15, 54   | 22.4 | 4 |
| 42 | When should preemptive antiviral therapy for active CMV infection be withdrawn from allogeneic stem cell transplant recipients?. <i>Bone Marrow Transplantation</i> , <b>2017</b> , 52, 1448-1451  | 4.4  | 3 |
| 41 | Synergistic Antioncogenic Activity of Azacitidine and Curcumin in Myeloid Leukemia Cell Lines and Patient Samples. <i>Anticancer Research</i> , <b>2019</b> , 39, 4757-4766  | 2.3  | 3 |
| 40 | Spontaneously-resolving episodes of cytomegalovirus DNAemia in allogeneic hematopoietic stem cell transplant recipients: Virological features and clinical outcomes. <i>Journal of Medical Virology</i> , <b>2019</b> , 91, 1128-1135  | 19.7 | 3 |
| 39 | Severe thrombocytopenia in myelofibrosis is more prevalent than previously reported. <i>Leukemia Research</i> , <b>2020</b> , 91, 106338   | 2.7  | 3 |
| 38 | Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method. <i>Annals of Hematology</i> , <b>2016</b> , 95, 719-32 | 3    | 3 |
| 37 | Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis. <i>Annals of Hematology</i> , <b>2019</b> , 98, 2319-2328   | 3    | 3 |
| 36 | Sustained complete molecular remission after imatinib discontinuation due to severe aplastic anemia. <i>Leukemia Research</i> , <b>2009</b> , 33, 589-92   | 2.7  | 3 |
| 35 | Kinetics of Torque Teno virus DNA in stools may predict occurrence of acute intestinal graft versus host disease early after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , <b>2021</b> , 23, e13507   | 2.7  | 3 |
| 34 | Allogeneic haematopoietic cell transplantation for myelofibrosis: proposed definitions and management strategies for graft failure, poor graft function and relapse: best practice recommendations of the EBMT Chronic Malignancies Working Party. <i>Leukemia</i> , <b>2021</b> , 35, 2445-2459         | 10.7 | 3 |
| 33 | Cytoreductive treatment in patients with CALR-mutated essential thrombocythaemia: a study comparing indications and efficacy among genotypes from the Spanish Registry of Essential Thrombocythaemia. <i>British Journal of Haematology</i> , <b>2021</b> , 192, 988-996                                 | 4.5  | 3 |
| 32 | Features of Cytomegalovirus DNAemia Blips in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Implications for Optimization of Preemptive Antiviral Therapy Strategies. <i>Biology of Blood and Marrow Transplantation</i> , <b>2020</b> , 26, 972-977  | 4.7  | 2 |
| 31 | Refractory cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation: when should genotypic drug resistance testing be requested?. <i>Bone Marrow Transplantation</i> , <b>2018</b> , 53, 787-790   | 4.4  | 2 |
| 30 | Monitoring of oral cytomegalovirus DNA shedding for the prediction of viral DNAemia in allogeneic hematopoietic stem cell transplant recipients. <i>Journal of Medical Virology</i> , <b>2018</b> , 90, 1375-1382  | 19.7 | 2 |
| 29 | Second versus first wave of COVID-19 in patients with MPN.. <i>Leukemia</i> , <b>2022</b> ,  | 10.7 | 2 |
| 28 | Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis. <i>Medicina Clínica</i> , <b>2020</b> , 155, 152-158   | 1    | 2 |
| 27 | Validation of a plasma metabolomics model that allows anticipation of the occurrence of cytomegalovirus DNAemia in allogeneic stem cell transplant recipients. <i>Journal of Medical Microbiology</i> , <b>2018</b> , 67, 814-819  | 3.2  | 2 |
| 26 | Cytomegalovirus DNA load monitoring in stool specimens for anticipating the occurrence of intestinal acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation: Is it of any value?. <i>Transplant Infectious Disease</i> , <b>2020</b> , 22, e13440                  | 2.7  | 2 |



|    |   |      |   |
|----|---|------|---|
| 25 | The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 2040-2043   | 1.9  | 2 |
| 24 | Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 2160-2172   | 4.4  | 2 |
| 23 | Factors influencing cytomegalovirus DNA load measurements in whole blood and plasma specimens from allogeneic hematopoietic stem cell transplant recipients. <i>Diagnostic Microbiology and Infectious Disease</i> , <b>2019</b> , 94, 22-27                                  | 2.9  | 2 |
| 22 | Genomic characterization of patients with polycythemia vera developing resistance to hydroxyurea. <i>Leukemia</i> , <b>2021</b> , 35, 623-627   | 10.7 | 2 |
| 21 | Kinetics of inflammatory biomarkers in plasma predict the occurrence and features of cytomegalovirus DNAemia episodes in allogeneic hematopoietic stem cell transplant recipients. <i>Medical Microbiology and Immunology</i> , <b>2019</b> , 208, 405-414                    | 4    | 1 |
| 20 | Assessment of immunodeficiency scoring index performance in enterovirus/rhinovirus respiratory infection after allogeneic hematopoietic stem cell transplantation. <i>Transplant Infectious Disease</i> , <b>2020</b> , 22, e13301  | 2.7  | 1 |
| 19 | Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H-DNMT3A mutated clone of patient origin. <i>Experimental and Molecular Pathology</i> , <b>2018</b> , 105, 139-143                 | 4.4  | 1 |
| 18 | Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , <b>2021</b> ,       | 4.4  | 1 |
| 17 | Cost-effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain. <i>Journal of Health Economics and Outcomes Research</i> , <b>2017</b> , 5, 162-174   | 1.6  | 1 |
| 16 | Peripheral blood regulatory T cells and occurrence of Cytomegalovirus DNAemia after unmanipulated haploidentical allogeneic hematopoietic stem cell transplantation with posttransplant cyclophosphamide. <i>Bone Marrow Transplantation</i> , <b>2020</b> , 55, 1493-1496    | 4.4  | 1 |
| 15 | Clinical significance of Pneumocystis jirovecii DNA detection by real-time PCR in hematological patient respiratory specimens. <i>Journal of Infection</i> , <b>2020</b> , 80, 578-606  | 18.9 | 1 |
| 14 | Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis. <i>Medicina Clínica (English Edition)</i> , <b>2020</b> , 155, 152-158  | 0.3  | 1 |
| 13 | Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 1823-1832  | 1.9  | 1 |
| 12 | Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis. <i>EJHaem</i> , <b>2021</b> , 2, 236-248   | 0.9  | 1 |
| 11 | Outcomes following second allogeneic haematopoietic cell transplantation in patients with myelofibrosis: a retrospective study of the Chronic Malignancies Working Party of EBMT. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 1944-1952                            | 4.4  | 1 |
| 10 | Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 1186-1194                          | 7.1  | 1 |
| 9  | Pharmacokinetic/Pharmacodynamic Analysis of Voriconazole Against Candida spp. and Aspergillus spp. in Allogeneic Stem Cell Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 740-747  | 3.2  | 1 |
| 8  | Failure of Cytomegalovirus-Specific CD8+ T Cell Levels at Viral DNAemia Onset to Predict the Eventual Need for Preemptive Antiviral Therapy in Allogeneic Hematopoietic Stem Cell Transplant Recipients. <i>Journal of Infectious Diseases</i> , <b>2019</b> , 219, 1510-1512 | 7    | 1 |

|   |  |     |   |
|---|--|-----|---|
| 7 | Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , <b>2021</b> , 56, 1593-1602 | 4.4 | 1 |
| 6 | CAR-T therapy in solid transplant recipients with post-transplant lymphoproliferative disease: case report and literature review. <i>Current Research in Translational Medicine</i> , <b>2021</b> , 69, 103304   | 3.7 | 1 |
| 5 | Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry.. <i>Leukemia Research</i> , <b>2022</b> , 115, 106821  | 2.7 | 0 |
| 4 | Absence of mutations in the activation loop and juxtamembrane domains of VEGFR-1 and VEGFR-2 gene in chronic myelomonocytic leukemia (CMML). <i>Leukemia Research</i> , <b>2012</b> , 36, e50-1  | 2.7 |   |
| 3 | Prognostic Factors in Classic Myeloproliferative Neoplasms <b>2011</b> , 85-96   |     |   |
| 2 | Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT.. <i>British Journal of Haematology</i> , <b>2022</b> ,   | 4.5 |   |
| 1 | Outcomes of allogeneic haematopoietic cell transplantation for chronic neutrophilic leukaemia: A combined CIBMTR / CMWP of EBMT analysis. <i>British Journal of Haematology</i> ,  | 4.5 |   |